Intravenous Immunoglobulin (IVIg) for Refractory and Difficult-to-treat Infections

被引：36
|
作者：
Ferrara, Giovanni [2 ,3 ]
Zumla, Alimuddin [4 ]
Maeurer, Markus [1 ,2 ]
机构：
[1] Karolinska Inst, Dept Microbiol Tumor & Cell Biol MTC, SE-17182 Stockholm, Sweden
[2] Karolinska Univ Hosp, Ctr Allogene Stem Cell Transplantat CAST, Stockholm, Sweden
[3] Univ Perugia, Sect Resp Dis, S Maria Hosp, Terni, Italy
[4] UCL, Sch Med, Div Infect & Immun, London W1N 8AA, England
来源：
AMERICAN JOURNAL OF MEDICINE | 2012年 / 125卷 / 10期
基金：
英国医学研究理事会;
关键词：
Clinical use; Difficult-to-treat infection; Immune response; Intravenous immunoglobulin; Tuberculosis; RED-CELL APLASIA; BACTERIAL-INFECTIONS; REPLACEMENT THERAPY; MULTIPLE-SCLEROSIS; ALZHEIMERS-DISEASE; GAMMA AUTOANTIBODY; DENDRITIC CELLS; HIV-INFECTION; LUNG-DISEASE; ANTIBODIES;
D O I：
10.1016/j.amjmed.2012.01.023
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Traditionally, intravenous immunoglobulin (IVIg) has been used as replacement therapy for patients with primary or secondary immunoglobulin deficiencies. Increasingly, IVIg is being used (in doses higher than for replacement therapy) in certain bacterial or viral infectious diseases. A variety of modes of action have been attributed to the beneficial effects of IVIg, including its interaction with T-cell function, antigen-presenting cell maturation/presentation, combined with a general "tune down" effect on inflammatory reactions. More often, IVIg is being evaluated in clinical trials for the treatment of refractory and difficult-to-treat chronic infections. The evidence, molecular mechanisms, and rationale for the use of adjunct IVIg therapy in infectious diseases are reviewed, and its potential use in the adjunct treatment of difficult-to-treat drug-resistant tuberculosis discussed. (C) 2012 Elsevier Inc. All rights reserved. The American Journal of Medicine (2012) 125, 1036.e1-1036.e8
引用
收藏
页数：8
相关论文
共 50 条
  • [21] Scedosporiosis and lomentosporiosis: modern perspectives on these difficult-to-treat rare mold infections
    Neoh, Chin Fen
    Chen, Sharon C-A
    Lanternier, Fanny
    Tio, Shio Yen
    Halliday, Catriona L.
    Kidd, Sarah E.
    Kong, David C. M.
    Meyer, Wieland
    Hoenigl, Martin
    Slavin, Monica A.
    [J]. CLINICAL MICROBIOLOGY REVIEWS, 2024, 37 (02)
  • [22] Severe infections caused by difficult-to-treat Gram-negative bacteria
    Dettori, Silvia
    Portunato, Federica
    Vena, Antonio
    Giacobbe, Daniele Roberto
    Bassetti, Matteo
    [J]. CURRENT OPINION IN CRITICAL CARE, 2023, 29 (05) : 438 - 445
  • [23] MANAGING DIFFICULT-TO-TREAT PATIENTS
    Llorca, P-M.
    [J]. EUROPEAN PSYCHIATRY, 2012, 27
  • [24] Surgically Difficult-to-Treat Meningiomas
    Duba, M.
    Mrlian, A.
    Neuman, E.
    Musil, J.
    Smrcka, M.
    [J]. CESKA A SLOVENSKA NEUROLOGIE A NEUROCHIRURGIE, 2015, 78 (01) : 88 - 92
  • [25] The difficult-to-treat psychiatric patient
    McCormick, S
    [J]. PSYCHIATRIC SERVICES, 2002, 53 (07) : 905 - 905
  • [26] Difficult-to-Treat Asthma in Childhood
    Alexandra Adams
    Sejal Saglani
    [J]. Pediatric Drugs, 2013, 15 : 171 - 179
  • [27] The Burden of the Serious and Difficult-to-Treat Infections and a New Antibiotic Available: Cefiderocol
    Taheri, Yasaman
    Jokovic, Natasa
    Vitorovic, Jelena
    Grundmann, Oliver
    Maroyi, Alfred
    Calina, Daniela
    [J]. FRONTIERS IN PHARMACOLOGY, 2021, 11
  • [28] CHEMOTHERAPEUTIC PRINCIPLES OF DIFFICULT-TO-TREAT INFECTIONS IN SURGERY .1. PERITONITIS
    WITTMANN, DH
    [J]. INFECTION, 1980, 8 (06) : 323 - 329
  • [29] CHEMOTHERAPEUTIC PRINCIPLES OF DIFFICULT-TO-TREAT INFECTIONS IN SURGERY .2. BONE AND JOINT INFECTIONS
    WITTMANN, DH
    [J]. INFECTION, 1980, 8 (06) : 330 - 333
  • [30] Difficult-to-Treat Asthma in Childhood
    Adams, Alexandra
    Saglani, Sejal
    [J]. PEDIATRIC DRUGS, 2013, 15 (03) : 171 - 179
12345